Drug intelligence / Profile preview

compound 11c

Development stage: Unknown
Lead developer: Gwangju Institute of Science and Technology
Modality: Small Molecules
Administration: Oral

Overview

Compound 11c is a novel peripheral 5HT2A receptor antagonist developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD). It demonstrates potent anti-inflammatory and anti-fibrotic effects in preclinical models. The compound shows good in vitro activity, stability, and favorable in vivo pharmacokinetics in rats and dogs with over 60% oral bioavailability. Tissue distribution studies using [14C]-labeled 11c confirmed it as a peripheral 5HT2A antagonist that doesn't significantly cross the blood-brain barrier.

Targets

HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on compound 11c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 11c.

Explore the full profile